RE: It's finally getting noticed.19 Mar 2021 09:11
Retire – You make some interesting points about the costs and position of the breathalyser development. The breathalyser will require regulatory approval and from the tiny number of tests done to date it must be reasonably assumed that this has not started. Regulatory approval will probably involve double blind trials. It is quite likely that these trials will need to be on all ethnicities, a range of ages and male/female. There will need to be a range of testing conditions eg temperature differences – no good if it does not work outside a freezing football stadium in January. The number of tests required will be at least in the thousands and more likely tens of thousands before approval is given to allow access to mass concerts etc.
There are a number of practical issues. It is unlikely that the UK or Ireland have enough Covid cases given the rapid fall in cases in the last few weeks to find enough people to test on, so where to go? If it is double blind there are ethical and legal issues. These are the types of issues that require deep pockets and experience of which DVRG has neither.
There needs to be a clear route to market. The idea that this will sell itself is fanciful. There are numerous examples of the best technology being beaten by inferior technology (ever heard of Betamax?). How will they manufacture? A marketing disaster would be not have units available. If there really was demand how would they fund millions of kits? Management have talked of the razor model but that would require deep pockets to fund the manufacture and distribution. This all needs to happen quickly because, as a number of posters have recognised, there are a number of other breathalysers under development.
To be honest the idea that DVRG has completed the funding of the development as Retire suggests is ludicrous. They have barely started – I would suspect that they are nearer 10% than 100% of the costs which Retire suggests. The lack of development progress since the AGM is startlingly slow. In the AGM presentation (which seems to have mysteriously disappeared from the website) management said that everything was pretty much ‘sorted’ - that is grossly misleading. It is not just the financial cost to commercialise the product but it also requires expertise and knowledge built up over decades. This is why most small companies bring in a major partner. This has not happened, although it is the stated strategy of the company to work with partners. Given that DVRG clearly does not have the finances or team to commercialise the breathalyser there will be many who will assume that there is little or no interest from a significant partner.
If DVRG bring in a government or commercial partner then that brings great credibility, an asset that tis sorely required ATM. Without that they have very little, at best. They have been working on this for months without notable commercial success and I fear that events will overtake them as the SP indicates.